Discovery of a Novel Series of Imidazo[1,2-<i>a</i>]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A<sub>2</sub> Inhibitors
作者:Xinde Chen、Wenwei Xu、Kai Wang、Mingguang Mo、Wei Zhang、Lili Du、Xiaojing Yuan、Yechun Xu、Yiping Wang、Jianhua Shen
DOI:10.1021/acs.jmedchem.5b01024
日期:2015.11.12
therapeutic strategy for several inflammation-associated diseases, including atherosclerosis, Alzheimer’s disease, and diabetic macular edema. Herein, we report the discovery of a novel series of Lp-PLA2 inhibitors constructed on an imidazo[1,2-a]pyrimidine scaffold through a conformational restriction strategy. Structure–activity relationship (SAR) analysis resulted in the identification of several compounds
脂蛋白相关的磷脂酶A 2(Lp-PLA 2)的抑制已被认为是一种对多种炎症相关疾病(包括动脉粥样硬化,阿尔茨海默氏病和糖尿病性黄斑水肿)的有前途的治疗策略。在这里,我们报道了通过构象限制策略在咪唑并[1,2- a ]嘧啶骨架上构建的一系列新的Lp-PLA 2抑制剂的发现。通过结构-活性关系(SAR)分析,鉴定出了几种化合物,它们在体外具有很高的效能,并且在肝脏S9组分中具有良好的代谢稳定性。选择化合物7c和14b进行进一步探索体内给药后,SD大鼠体内表现出优异的药代动力学特征,并表现出显着的抑制作用。